Today: 2 July 2026
Browse Category

NYSE:LLY 7 January 2026 - 13 January 2026

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

New York, Jan 13, 2026, 11:51 EST — Regular session Shares of Eli Lilly and Company inched up 0.2% to $1,083.63 on Tuesday, fluctuating between $1,070 and $1,090 as roughly 736,000 shares exchanged hands. The move followed the U.S. Food and Drug Administration's request that drugmakers strip suicide-related warnings from labels on GLP-1 weight-loss medications, including Lilly’s Zepbound and Novo Nordisk’s Wegovy.
13 January 2026
···
Nvidia stock in premarket: H200 China payment clarification, Lilly AI lab and TSMC earnings in focus

Nvidia stock in premarket: H200 China payment clarification, Lilly AI lab and TSMC earnings in focus

New York, Jan 13, 2026, 08:38 EST — Premarket Nvidia shares showed little movement in premarket trading Tuesday following the company’s announcement that customers won’t need to pay upfront for its H200 chip, a data-center GPU designed for AI model training and deployment. The stock inched up roughly 0.03% to $184.94.
13 January 2026
·····
Eli Lilly stock moves after-hours on fast-track weight-loss pill talk and Nvidia AI lab deal

Eli Lilly stock moves after-hours on fast-track weight-loss pill talk and Nvidia AI lab deal

New York, January 12, 2026, 5:46 PM EST — After-hours Eli Lilly stock rose about 1.6% in after-hours trading on Monday, last at $1,081, after a top research executive said the drugmaker expects to have enough supply to launch its experimental weight-loss pill orforglipron in “many, many countries” as it nears a U.S. regulatory decision.
13 January 2026
···
Nvidia stock wobbles after $1B Eli Lilly AI lab plan as CPI and TSMC loom

Nvidia stock wobbles after $1B Eli Lilly AI lab plan as CPI and TSMC loom

NEW YORK, Jan 12, 2026, 10:43 a.m. ET — Regular session Nvidia, the world’s most valuable listed company, and Eli Lilly said on Monday they will spend $1 billion over five years on a joint research lab in the San Francisco Bay Area, betting Nvidia’s next Vera Rubin AI chips can speed drug discovery. Nvidia shares were down 0.2% at $184.42 by 10:30 a.m. ET.
12 January 2026
····
Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Schrödinger announced it will integrate Eli Lilly’s TuneLab, an AI-driven drug discovery platform, into its LiveDesign software. This move offers biotech teams direct access to Lilly’s predictive models. “LiveDesign will be a priority platform partner for TuneLab workflows,” said Pat Lorton, Schrödinger’s software chief. The deal comes as drugmakers ramp up AI efforts to speed candidate identification and detect safety concerns earlier—a push gaining momentum amid regulatory pressure to reduce animal testing. LiveDesign aids chemists in designing compounds and forecasting properties like absorption and distribution, key to understanding how drugs enter and move through the body. Schrödinger plans to launch TuneLab to current LiveDesign users in Q1, expanding to new clients in Q2, said Karen Akinsanya, the company’s chief strategy officer. Lilly expects broader adoption to improve the models: “More biotechs using the models means more diverse training data,” noted Aliza Apple, global head of Lilly TuneLab.
10 January 2026
····
Eli Lilly stock (LLY) slips as Ventyx deal, Zepbound arthritis data and TuneLab AI tie-up come into view

Eli Lilly stock (LLY) slips as Ventyx deal, Zepbound arthritis data and TuneLab AI tie-up come into view

New York, Jan 9, 2026, 11:27 EST — Regular trading Eli Lilly and Company shares were down about 0.4% at $1,081 in morning trade on Friday. The drugmaker said this week it will buy autoimmune developer Ventyx Biosciences for $1.2 billion in cash, bringing oral candidates for inflammatory bowel disease into its pipeline. The $14-a-share offer is slated to close in the first half of 2026, and Cantor Fitzgerald analyst Carter Gould described the price as “borderline immaterial” for Lilly.
9 January 2026
···
Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

New York, Jan 8, 2026, 18:23 EST — After-hours Shares of Eli Lilly fell 2.1% on Thursday, trading between $1,070.16 and $1,133.06, and were last at $1,085.19 in after-hours activity after the drugmaker reported late-stage data on a Zepbound-Taltz combination in psoriatic arthritis. Lilly said 31.7% of patients on the combo met a dual goal — at least 50% lower disease activity and at least 10% weight loss after 36 weeks — compared with 0.8% on Taltz alone. Senior vice president Mark Genovese said the results support an “integrated treatment approach” for the inflammatory joint disease, which affects up to a third of people with psoriasis; nausea, diarrhea and constipation were among the most common side effects, Lilly said. Reuters
9 January 2026
··
Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

New York, Jan 8, 2026, 08:36 EST — Premarket Eli Lilly shares were up 4.1% at $1,108.09 in premarket trade on Thursday after the drugmaker agreed to buy autoimmune-focused biotech Ventyx Biosciences for $1.2 billion in cash. The deal adds oral drugs for inflammatory diseases and a mid-stage program tied to a cardiovascular condition linked to obesity. “We like that Lilly is taking chances on potentially transformative opportunities,” Cantor Fitzgerald analyst Carter Gould said. Reuters
8 January 2026
·
Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

New York, Jan 7, 2026, 4:55 PM EST — After-hours Eli Lilly and Co shares climbed on Wednesday after the drugmaker agreed to buy Ventyx Biosciences in a $1.2 billion deal, pressing ahead with its push beyond blockbuster diabetes and weight-loss drugs. Lilly stock ended up 4.1% at $1,108.09, after touching $1,117.37, for a market value around $1 trillion. reuters.com
7 January 2026
···
1 … 4 5 6 7 8 … 13

Stock Market Today

  • Haleon CFO Dawn Allen Gets Share Award, Sells Part to Pay Tax
    July 2, 2026, 10:30 AM EDT. Haleon PLC (LSE/NYSE: HLN) said CFO Dawn Allen was given a Performance Share Plan award that vests June 30, 2026. She got 283,193 shares under the 2024 plan, based on targets through December 2025. Allen sold 133,301 shares at £3.52 each in London to cover taxes owed from the vesting. Shares include dividends and are subject to malus and clawback. The company made the disclosure under UK rules and reminded that execs have to hold shares for two years after they vest. Details will be in next year's annual report and 20-F.
Go toTop